Allegra Orthopaedics Limited provided the following update on its innovation project, the Sr-HT-Gahnite Spinal Cage Device (Spinal Cage): Further to Allegra's ASX announcement of December 21, 2020, where the company advised the dynamic torsion, compression and tests had passed the regulatory-required 5 million cycles without any signs of fracture or failure, Allegra is now pleased to report the successful completion of the 8 week timeline for the large animal pilot study performed at SAHMRI (South Australian Health and Medical Research Institute). CT imaging taken at intervals throughout the study show stable implants with complete fusion in both lumbar and cervical zones, confirming the Spinal Cage performs as intended. Allegra will now strive to reproduce these outcomes in a 6 month large animal trial in Australia, with the intention of obtaining approval from the Federal Drug Administration (`FDA') in the United States. The results of the 8 week animal study mark a pivotal milestone and a confirm a viable pathway to obtaining a 90 day FDA 510(k) clearance in the near future. In addition Allegra finalized its manufacturing process of the Spinal Cage and will now enter final validation and verification testing. The commencement of these tests and ultimately their completion represent some of the final steps towards Allegra's submission to Australia's Therapeutic Goods Administration (`TGA') in November this year. Allegra Orthopaedics is the sole proprietor of the Sr-HT-Gahnite material and aims to apply the technology to fulfilling unmet needs across a broad range of applications including both Spine, Hip & Knee and extremities.